Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472769 · ClinicalTrials.gov registry record · Phase 2
IBP-9414 for the Prevention of Necrotizing Enterocolitis
A Phase 2 study of Necrotizing Enterocolitis, sponsored by Infant Bacterial Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 15
- Study locations
NCT02472769 is a Phase 2 study of Necrotizing Enterocolitis that has completed, run by Infant Bacterial Therapeutics. The registered enrollment target is 120 participants, below the 305-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (61% lower). The trial reports 15 study locations across 10 states.
The verdict
NCT02472769, a Phase 2 study of Necrotizing Enterocolitis, has completed, sponsored by Infant Bacterial Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 15
- Study locations
Study Summary
Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IBP-9414
Study Locations (15)
Florida
- University Florida Health - Gainesville
- Wolfson Children´s Hospital - Jacksonville
- UF Health Jacksonville - Jacksonville
- Jackson Memorial Hospital - Miami
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University Health Sciences - Winston-Salem
Pennsylvania
- Hahnemann University Hospital - Philadelphia
- Einstein Medical Center of Philadelphia - Philadelphia
Arkansas
- Univ. Arkansas Medical Sciences - Little Rock
California
- UCLA Medical Center - Los Angeles
Indiana
- Memorial Hospital of South Bend - South Bend
Kansas
- Wesley Medical Center - Wichita
New York
- Kings County Hospital Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2017-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02472769
The ClinicalTrials.gov registry entry for NCT02472769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (61% lower). The listed sponsor is Infant Bacterial Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Necrotizing Enterocolitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02472769 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Florida, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02472769 about?
NCT02472769 is a clinical study titled "IBP-9414 for the Prevention of Necrotizing Enterocolitis". Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.
What is the current status of trial NCT02472769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2016-05-27. Estimated completion is 2017-08-07.
What conditions does trial NCT02472769 study?
This clinical trial studies the following conditions: Necrotizing Enterocolitis.
What interventions are being tested in trial NCT02472769?
The interventions under investigation include: Placebo (DRUG), IBP-9414 (DRUG).
Who is sponsoring clinical trial NCT02472769?
This trial is sponsored by Infant Bacterial Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02472769 being conducted?
This trial has 15 study locations across Arkansas, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Necrotizing Enterocolitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RIC-NEC Randomized Controlled Trial
ACTIVE NOT RECRUITING · Phase 2
-
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
COMPLETED · Phase 2
-
Early Predictors of Necrotizing Enterocolitis in Neonates
RECRUITING
-
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
RECRUITING · Phase 1
-
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
RECRUITING · NA
-
A Cohort Study of the Intestinal Microbiota of Premature Infants
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.